Apoptotic cascades as possible targets for inhibiting cell death in Huntington's disease

Journal of Neurology

Volumn 253, Issue 9, 2006, Pages 1137-1142

  Pattison, Lindsay R ^a   Kotter, Mark R ^b   Fraga, Dean ^a   Bonelli, Raphael M ^c  

^a 931 College Mall   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Apoptosis; Huntington's disease; Minocycline; Neurodegeneration; Neuroprotection

Indexed keywords

ANTIBIOTIC AGENT; CASPASE; MINOCYCLINE; TETRACYCLINE;

ANTIINFLAMMATORY ACTIVITY; AUTOSOMAL DOMINANT DISORDER; CELL DEATH; CELL SURVIVAL; DISEASE COURSE; HUMAN; HUNTINGTON CHOREA; MEDICAL RESEARCH; MICROGLIA; NERVE DEGENERATION; NEUROPROTECTION; NEUROPSYCHIATRY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; APOPTOSIS; HUMANS; HUNTINGTON DISEASE; MINOCYCLINE; MODELS, BIOLOGICAL; NEURAL INHIBITION;

EID: 33749437310     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-006-0198-8     Document Type: Review

References (57)

1. Almqvist E, Spence N, Nichol K, Andrew SE, Vesa J, Peltonen L, et al. (1995) Ancestral differences in the distribution of the delta 2642 glutamic acid polymorphism is associated with varying CAG repeat lengths on normal chromosomes: insights into the genetic evolution of Huntington's disease. Hum Mol Genet 4:207-214
2. Arregui L, Segovia J (2004) Molecular Strategies for the Treatment of Huntington's Disease. Curr Pharmacogenom 2:299-311
3. Barone FC, Feuerstein GZ (1999) Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab 19:819-834
4. Beal MF (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38:357-366
5. Berger, Abi (2000) Minocycline slows progress of Huntington's disease in mice. BMJ 321:70
6. Bonelli RM, Heuberger C, Reisecker F (2003) Minocycline for Huntington's Disease: An open label study. Neurology 60:883-884
7. Bonelli RM, Hödl AK, Hofmann P, Kapfhammer HP (2004) Neuroprotection in Huntington's disease: a 2-year study on minocycline. Intl Clin Psychopharmacol 19:337-342
8. Brinkman RR, Mezei MM, Theilmann J, Almqvist E, Hayden MR (1997) The likelihood of being affected with Huntington's disease at a particular age, for a specific CAG size. Am J Hum Genet 60:1202-1210
9. Carmichael J, Chatellier J, Woolfson A, Milstein C, Gersht AR, Rubinsztein DC (2000) Bacterial and Yeast Chaperones Reduce Both Aggregate Formation and Cell Death in Mammalian Cell Models of Huntington's Disease. Proc Natl Acad Sci U S A 97:9701-9705
10. Chan SL, Mattson MP (1999) Caspase and Calpain Substrates: Roles in Synaptic Plasticity and Cell Death. J Neurosci Res 58:167-190
11. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6:797-801
12. Clarke PGH (1990) Developmental Cell Death:morphological diversity and multiple mechanisms. Anat Embryol 181:195-213
13. Cooper NR, Kalaria RN, McGeer PL, Rogers J (2000) Key issues in Alzheimer's disease inflammation. Neurobiol Aging 21:451-453
14. Dirnagl U, Iadecola C, Moskowitz MA (1999) Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22:391-397
15. Ferrer I, Puig B, Krupinski J, Carmona M, Blanco R (2001) Fas and Fas ligand expression Alzheimer's disease. Acta Neuropathol (Berl) 102:121-131
16. Forno LS, Norville RL (1979) Ultrastructure of the neostriatum in Huntington's and Parkinson's disease. Adv Neurol 23:123-135
17. Friedlander, Robert M. (2003) Apoptosis and Caspases in Neurodegenerative Diseases. N Engl J Med 348:1365-1375
18. Gu Y, Wu J, Faucheu C, Lalanne JL, Diu A, Livingston DH, Su MS (1995) Interleukin-1 beta converting enzyme requires oligomerization for activity of processed forms in vivo. EMBO J 14:1923-1931
19. Harper PS (1996) Huntington's Disease. 2nd ed. Saunders, London
20. He Y, Appel S, Le W (2001) Minocycline inhibits microglial activation and protects nigral cells after 6-hydrozydopamine injection into mouse striatum. Brain Res 909:187-193
21. Hickey MA, Chesselet MF (2003) Apoptosis in Huntington's Disease. Prog Neuropsychopharmacol Biol Psychiatry 27:255-265
22. Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, Rosemond E, Roder JC, Phillips AG, Rubin EM, Hersch SM, Hayden MR (1999) A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23:181-192
23. Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosome. Cell 72:971-983
24. Kahlem P, Terre C, Green H, Djian P (1996) Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: relevance to diseases of the nervous system. Proc Natl Acad Sci U S A 93:14580-14585
25. Kegel KB, Meloni AR, Yi Y, Kim YJ, Doyle D, Cuiffo BG, et al. (2002) Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J Biol Chem 277:7466-7476
26. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD (1997) The release of cytochrome c from mitochondrial: a primary site for Bcl-2 regulation of apoptosis. Science 275:1132-1136
27. Koliatsos VE, Portera-Cailliau C, Schilling G, Borchelt DB, Becher MW, Ross CA (2001) Apoptosis in Huntington Disease and Animal Models. Adv Cell Aging Gerontol 6:205-223
28. Lee JM, Zipfel GJ, Choi DW (1999) The changing landscape of ischaemic brain injury mechanisms. Nature [Suppl 6738] 399:A7-A14
29. Li H, Zhu H, Xu CJ, Yuan J (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491-501
30. Mallat M, Marin-Teva JL, Cheret C (2005) Phagocytosis in the developing CNS: more than clearing the corpses. Curr Opin Neurobiol 15:101-107
31. McGeer EG, McGeer PL (1999) Brain inflammation in Alzheimer disease and the therapeutic implications. Curr Pharm Des 5:821- 836
32. Nakagawa T, et al. (2000) Caspase-12 mediates endoplasmic-reticulum- specific apoptosis and cytotoxicity by amyloid-β. Nature 403:98-103
33. Norremolle A, Riess O, Epplen JT, Fenger K, Hasholt L, Sorensen SA (1993) Trinucleotide repeat elongation in the Huntingtin gene in Huntington disease patients from 71 Danish families. Hum Mol Genet 2:1475- 1476
34. Passani LA, Bedford MT, Faber PW, McGinnis KM, Sharp AH, Gusella JF, et al. (2000) Huntingtin's WW domain partners in Huntington's disease postmortem brain fulfill genetic criteria for direct involvement in Huntington's disease pathogenesis. Hum Mol Genet 9:2175-2182
35. Perutz MF, Johnson T, Suzuki M, Finch JT (1994) Glutamine repeats as polar zippers: Their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci U S A 91:5355-5358
36. Rangone H, Humbert S, Saudou F (2004) Huntington's disease: how does huntingtin, an anti-apoptotic protein, become toxic? Pathol Biol 52:338-342
37. Rothwell NJ, Luheshi G, Toulmond S (1996) Cytokines and their receptors in the central nervous system: physiology, pharmacology, and pathology. Pharmacol Ther 69:85-95
38. Sapp E, Ge P, Aizawa H, Bird E, Penney J, Young AB, et al. (1995) Evidence for a preferential loss of enkephalin immunoreactivity in the eternal globus pallidus in low grade Huntington's disease using high resolution image analysis. Neuroscience 64:397-404
39. Saudou F, Finkbeiner S, Devys D, Greenberg ME (1998) Huntingtin Acts in the Nucleus to induce Apoptosis but Death Does Not Correlate with the formation of intranuclear inclusions. Cell 95:55-66
40. Sawa, Akira (2001) Mechanisms for neuronal cell death and dysfunction in Huntington's disease: pathological cross-talk between the nucleus and the mitochondria? J Mol Med 79:375-381
41. Sipione S, Cattaneo E (2001) Modeling Huntington's Disease in Cells, Flies, and Mice. Mol Neurobiol 23:21-51
42. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang HG, Reed JC, Nicholson DW, Alnemri ES, Green DR, Martin SJ (1999) Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2,-3,-6,-7,-8, and -10 in a caspase-9-dependent manner. J Cell Biol 144:281-292
43. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Litwack G, Alnemri ES (1996) Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. Proc Natl Acad Sci USA 93:14486-14491
44. Thornberry NA, Rosen A, Nicholson DW (1997) Control of Apoptosis by Proteases. Adv Pharmacol 41:155-177
45. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J (2001) Minocycline, a Tetracycline Derivative, Is Neuroprotective against Excitotoxicity by Inhibiting Activation and Proliferation of Microglia. J Neurosci 21:2580-2588
46. Touzani O, Boutin H, Chuquet J, Rothwell N (1999) Potential mechanisms of interleukin-1 involvement in cerebral ischaemia. J Neuroimmunol 100:203-215
47. Vila M, Przedborski S (2003) Targeting Programmed Cell Death in Neurodegenerative Diseases. Neuroscience 4:1-11
48. Vonsattel JP, DiFiglia M (1998) Huntington's Disease. J Neuropathol Exp Neurol 57:369-384
49. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson Jr., EP (1985) Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44:559-577
50. Vuillaume I, Vermersch P, Destee A, Petit H, Sablonniere B (1998) Genetic polymorphisms adjacent to the CAG repeat influence clinical features at onset in Huntington's disease. J. Neurol. Neurosurg. Psychiatry 64:758-762
51. Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S et al. (2002) Caspase Cleavage of Mutant Huntingtin Precedes Neurodegeneration in Huntington's Disease. J Neurosci 22:7862-7872
52. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X (1997) Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275:1129-1132
53. Yrjanheikki J, Keinänen R, Pellikka M, Hökfelt T, Koistinaho J (1998) Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A 95:15769 -15774
54. Yrjanheikki J, Tikka T, Keinänen R, Goldsteins G, Chan PH, Koistinaho J (1999) A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A 96:13496-13500
55. Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, Efstratiadis A (1995) Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 11:155-163
56. Zhu S, Stavrovskaya IG, Drozda M, et al. (2002) Minocycline inhibits cytochrome c release and delays progression of amytrophic lateral sclerosis in mice. Nature 417:74-78
57. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, et al. (2001) Loss of huntingtin-mediated bDNF gene transcription in Huntington's disease. Science 293:493-498